Search

Search Constraints

You searched for: Date 2023 Author/Creator Ferrante, M

Search Results

1. A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL. (7th March 2023)

2. A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL. (7th March 2023)

3. OP01 Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn's disease. (30th January 2023)

4. OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial. (30th January 2023)

5. OP13 Postoperative Crohn's disease recurrence: unanswered questions and future directions in diagnosis, pathophysiology, prevention and treatment. Conclusions from the 8th ECCO Scientific workshop. (30th January 2023)

6. OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies. (30th January 2023)

7. OP19 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey. (30th January 2023)

9. P008 Fibrostricturing Crohn's disease is characterised by an imbalance in active eosinophils, Th1, Th2 and regulatory T cells. (30th January 2023)